Extended Data Fig. 1: Statistical identification of a baseline serum IL-8 cutoff below which patients were more likely to benefit from Nivo-based therapy. | Nature Medicine

Extended Data Fig. 1: Statistical identification of a baseline serum IL-8 cutoff below which patients were more likely to benefit from Nivo-based therapy.

From: Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors

Extended Data Fig. 1

ROC curve analyses were used to assess ORR, 6-month PFS, and 12-month OS. OS AUC (12-month) is indicated and identifies ≥23 pg/ml as a cutoff. All cases with nivolumab-containing therapies were analyzed. AUC, area under the curve; Nivo, nivolumab; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; ROC, receiver operator characteristic.

Back to article page